Mereo BioPharma Announces Option And License Agreement With Zydus Unit Sentynl For US Rights To Alvelestat In AATD-LD; Eligible For $40M Upfront On Option Exercise, Up To $435M In Milestones
Share
Why It Matters
Mereo BioPharma made a deal to let another company help sell their medicine in the US, and could earn up to $475 million if things go well. When companies partner up like this, it shows others believe in their product, which is worth watching.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.